Updated results from the skin cancer cohorts from an ongoing phase 1/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE).

Milhem, MM, Vanderwalde, AM, Bowles, TL et al. (16 more authors) (2022) Updated results from the skin cancer cohorts from an ongoing phase 1/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Illinois.

Metadata

Authors/Creators:
  • Milhem, MM
  • Vanderwalde, AM
  • Bowles, TL
  • Sacco, JJ
  • Niu, J
  • Tsai, KK
  • Chesney, JA
  • Chmielowski, B
  • Samson, A ORCID logo https://orcid.org/0000-0002-3081-7850
  • Rhodes, TD
  • In, GK
  • Pavlick, AC
  • Wise-Draper, TM
  • Sanmamed, MF
  • Bommareddy, P
  • Zhu, J
  • Coffin, RS
  • Harrington, KJ
  • Middleton, MR
Dates:
  • Published: 1 June 2022
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 22 Nov 2022 15:04
Last Modified: 22 Nov 2022 15:04
Status: Published
Identification Number: https://doi.org/10.1200/JCO.2022.40.16_suppl.9553
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)